Jump to content

Ibandronic acid

From Wikipedia, the free encyclopedia

Ibandronic acid
Clinical data
Trade namesBoniva, Bonviva, Bondronat, others
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability0.6%
Protein binding90.9 to 99.5%
(concentration-dependent)
MetabolismNil
Elimination half-life10 to 60 hours
ExcretionKidney
Identifiers
  • Hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.214.537 Edit this at Wikidata
Chemical and physical data
FormulaC9H23NO7P2
Molar mass319.231 g·mol−1
3D model (JSmol)
  • O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O
  • InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) checkY
  • Key:MPBVHIBUJCELCL-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.[4] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium.[medical citation needed]

It was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996.[5]

Medical uses

[edit]

Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.[6] In May 2003, the US Food and Drug Administration (FDA) approved ibandronate as a daily treatment for post-menopausal osteoporosis.[medical citation needed] The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis.[medical citation needed] Each participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D.[medical citation needed] At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.[medical citation needed]

Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.[7]

Adverse effects

[edit]

In 2008, the US Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain.[8] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur.[9] The drug also has been associated with osteonecrosis of the jaw, a relatively rare but serious condition.[10]

Pharmacology

[edit]
Relative potency[11]
Bisphosphonate Relative potency
Etidronate 1
Tiludronate 10
Pamidronate 100
Alendronate 100-500
Ibandronate 500-1000
Risedronate 1000
Zoledronate 5000

Society and culture

[edit]

Brand names

[edit]

Ibandronic acid is sold under the brand names Boniva, Bondronat, Bonviva, Bandrone, Ibandrix, Adronil, Bondrova, Bonprove, and Fosfonat.

References

[edit]
  1. ^ "Bondronat EPAR". European Medicines Agency (EMA). 25 June 1996. Retrieved 28 August 2024.
  2. ^ "Bonviva EPAR". European Medicines Agency (EMA). 23 February 2004. Retrieved 28 August 2024.
  3. ^ "Iasibon EPAR". European Medicines Agency (EMA). 21 January 2011. Retrieved 30 August 2024.
  4. ^ Bauss F, Schimmer RC (March 2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and Clinical Risk Management. 2 (1): 3–18. PMC 1661644. PMID 18360577.
  5. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495.
  6. ^ "Boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
  7. ^ Sittig HB (2012). "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie. 35 (6): 380–7. doi:10.1159/000338947. PMID 22722461. S2CID 8413102.
  8. ^ "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.
  9. ^ Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. (American Society for Bone and Mineral Research) (November 2010). "Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research". Journal of Bone and Mineral Research. 25 (11): 2267–2294. doi:10.1002/jbmr.253. PMID 20842676. S2CID 15194275.{{cite journal}}: CS1 maint: overridden setting (link); Lay summary in: "JBMR Publishes ASBMR Task Force Report on Atypical Femoral Fractures". Journal of Bone and Mineral Research. 14 September 2010. Archived from the original on 9 April 2016. Retrieved 27 October 2010.
  10. ^ "Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis" (PDF). United Kingdom: The National Osteoporosis Society. Archived from the original (PDF) on 17 June 2017. Retrieved 14 August 2018.
  11. ^ Tripathi KD (30 September 2013). Essentials of Medical Pharmacology (Seventh ed.). New Delhi: Jaypee Brothers Medical Publisher. ISBN 9789350259375. OCLC 868299888.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ibandronic_acid&oldid=1250042118"